On the same day that the first doses of Janssen arrived in Spain, the Johnson & Johnson vaccine against COVID-19 in which they had placed high hopes because it is a single-dose vaccine and with more logistical facilities (it does not need deep freezers) , came the jug of cold water: the United States, which had already administered almost seven million doses, asked to suspend its administration after detecting some cases of thrombi in that list of vaccinated. Six cases out of almost seven million. The pharmaceutical company itself suspended the administration worldwide.
It was expected since then, April 14, that the European Union would make a decision regarding this vaccine through the EMA (European Medicines Agency) to give the green light or not to its administration to European citizens. He just gave his verdict: recommends continuing to vaccinate with Janssen, so it is to be expected that the vaccination campaign that was planned with her will be resumed. In the case of Spain, the age group where it was planned to administer its first doses was between 70 and 79 years.
